Neurotez
Neurotez Inc. is developing a drug to treat Leptin deficiency in Alzheimer’s patients.
Overview
Raised: $95,809
Rolling Commitments ($USD)
Status
Funded
Reporting Date
02/28/2018
Days Remaining
Funded
% of Min. Goal
958%
% of Max. Goal
90%
Likelihood of Max
Funded
Avg. Daily Raise
$1,774
Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded
2005
Industry
Healthcare & Pharmaceuticals
Tech Sector
Biotech
Location
Bridgewater, New Jersey
Who Should Be Interested:
Are you, or is someone in your life, impacted by Alzheimer’s? Is so, Neurotez Inc. could be the investment you’ve been looking for. Their highly experienced team is developing a drug to treat Leptin deficiency in Alzheimer’s patients and/or act as a preventative for those who are at risk, and their drug might just be the missing piece needed to help fight this terrible disease.
The Company:
Neurotez Inc. is on a mission to become the world leaders in biotechnology and to help Alzheimer’s patients with drugs that are both safe and efficacious. Their primary goal is to develop a Leptin product as an innovative hormone replacement therapy for Alzheimer’s disease and/or as a preventative for those who are at risk. Today’s medications provide limited relief, and current efforts, which focus on removing either Abeta or tau deposits from the brain, have not generated any effective drugs for the last 18 years. Neurotez is here to change that -- by focusing on Leptin instead and attacking the disease in a new way. So far, Neurotez has been nominated as the Most Promising Private Company in 2015 by the Biotechnology Industry Organization, as well as a 2010 Incubator Company to Watch at the NJTC Gala Awards. Add in that their team has deep experience and success with thousands of publications in Alzheimer’s, and you can see why Neurotez might just be the Alzheimer's weapon we’ve been waiting for.
The Bottom Line:
Neurotez Inc. is changing the game when it comes to treating and fighting Alzheimer’s. Their Leptin product attacks the disease in a new way, and with Alzheimer’s affecting more than five million Americans and 18 million patients worldwide, we need all the help we can get. This innovative treatment might be just what patients need to help with -- or prevent -- the devastating effects of Alzheimer’s.
Are you, or is someone in your life, impacted by Alzheimer’s? Is so, Neurotez Inc. could be the investment you’ve been looking for. Their highly experienced team is developing a drug to treat Leptin deficiency in Alzheimer’s patients and/or act as a preventative for those who are at risk, and their drug might just be the missing piece needed to help fight this terrible disease.
The Company:
Neurotez Inc. is on a mission to become the world leaders in biotechnology and to help Alzheimer’s patients with drugs that are both safe and efficacious. Their primary goal is to develop a Leptin product as an innovative hormone replacement therapy for Alzheimer’s disease and/or as a preventative for those who are at risk. Today’s medications provide limited relief, and current efforts, which focus on removing either Abeta or tau deposits from the brain, have not generated any effective drugs for the last 18 years. Neurotez is here to change that -- by focusing on Leptin instead and attacking the disease in a new way. So far, Neurotez has been nominated as the Most Promising Private Company in 2015 by the Biotechnology Industry Organization, as well as a 2010 Incubator Company to Watch at the NJTC Gala Awards. Add in that their team has deep experience and success with thousands of publications in Alzheimer’s, and you can see why Neurotez might just be the Alzheimer's weapon we’ve been waiting for.
The Bottom Line:
Neurotez Inc. is changing the game when it comes to treating and fighting Alzheimer’s. Their Leptin product attacks the disease in a new way, and with Alzheimer’s affecting more than five million Americans and 18 million patients worldwide, we need all the help we can get. This innovative treatment might be just what patients need to help with -- or prevent -- the devastating effects of Alzheimer’s.
Create a free account today to gain access to KingsCrowd analytics.
Raise History
Offering Name | Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
---|---|---|---|---|---|---|---|
Neurotez | 01/27/2023 | Netcapital | $45,272,228 | $15,952 | Equity - Common | Funded | RegCF |
Neurotez | 03/10/2022 | StartEngine | $44,870,036 | $33,845 | Equity - Common | Funded | RegCF |
Neurotez | 06/24/2021 | Netcapital | $21,959,058 | $255,718 | Equity - Common | Funded | RegCF |
Neurotez | 02/26/2018 | Netcapital | $24,544,690 | $95,809 | Equity - Common | Funded | RegCF |
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.
Wall Street has Morningstar, S&P, and Bloomberg
The equity crowdfunding market has KingsCrowd.
Are you the founder of Neurotez? Create your account today to claim this raise page.